Integrins, a family of heterodimeric adhesion receptors for various extracellular matrices, have repeatedly been linked to being important initiators and promoters of ovarian cancer growth and progression. Aggressive ovarian tumors exhibit significantly elevated levels of several RGD-based integrin family members, including integrins 5-1 and v3 or v5. These adhesion receptors appear to encourage cell adhesion, survival, motility, and invasion during the development of an ovarian tumor or the spread of its metastatic disease. Notably, the activation of FAK and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways, is crucial for the functions of these integrins.
Transmembrane proteins called integrins serve as important receptors for cell-extracellular matrix (ECM) and cell-cell adhesion.These molecules can be modified, and the v integrin family in particular, has shown to have significant effects on fibrosis in a variety of organs and disease states. According to numerous studies, the latent transforming growth factor (TGF)- is activated by the integrins v3, v5, v6, and v8 in pre-clinical fibrosis models, modulating the fibrotic process.
One of the 18 different types of subunits that are known to exist and one of the eight different types of subunits that are known to exist are typically non-covalently paired to form each integrin. There are currently 24 different heterodimers in total. The fact that the v subunit can form heterodimers with the 1, 3, 5, 6 or 8 subunits and that the 1 subunit can associate with a wide variety of subunits from 1 to 11 shows that not all theoretically possible and subunit pairs form. It's intriguing to note that a variety of v integrins appear to share a common function in TGF- activation.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V76557 | RGD peptide (GRGDNP) (TFA) | RGD peptide (GRGDNP) TFA is an inhibitor (blocker/antagonist) of integrin-ligand interactions. | |
|
V38827 | RGD Trifluoroacetate | 2378808-45-6 | RGD Trifluoroacetate is a tripeptide that can effectively cause cell adhesion, localize to a specific cell line and produce specific cellular responses; RGD Trifluoroacetate can bind to integrins. |
|
V38790 | RGD-4C | 332179-76-7 | RGD-4C is an arginine-glycine-aspartate peptide (ACDCRGDCFC) with integrin-binding activity. |
|
V75804 | RGDSPASSKP | 91575-25-6 | RGDSPASSKP is a fibronectin decapeptide containing RGDS. |
|
V38273 | RO0270608 | 220846-33-3 | RO0270608, the bioactive metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. |
|
V38166 | Rovelizumab | 339086-79-2 | Rovelizumab is a humanized monoclonal leukocyte integrin antibody. |
|
V1600 | SB273005 | 205678-31-5 | SB273005 (SB 273005; SB-273005) is a novel and potent integrin inhibitor with potential usefulness in bone resorption, osteoporosis and arthritis. |
|
V35244 | Surfactin C1 | 24730-31-2 | Surfactin C1 is an amphiphilic biosurfactant. |
|
V53239 | Synstatin (92-119) (SSTN92-119) | 1259384-47-8 | Synstatin (92-119) is an antineoplastic/anticancer agent that can inhibit angiogenesis and cancer cell invasion. |
|
V35230 | Tadocizumab (C4G1; YM-337) | 339086-80-5 | Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody (mAb) targeting integrin αIIbβ3. |
|
V81545 | TC113 | TC113 is a c(RGDyK) conjugate of gemcitabine. | |
|
V3567 | THI0019 | 1378532-99-0 | THI-0019 (THI0019) is a novel and potentintegrin α4β1 (VLA-4)agonist (EC50 in the range of 1-2 μM). |
|
V1599 | Tirofiban (L700462; MK383) | 144494-65-5 | Tirofiban (formerly known as L-700462;MK-383;L700462; MK383; Aggrastat) is a novel non-peptide antagonist of glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) that has been approved for use as an antiplatelet drug. |
|
V3822 | Tirofiban hydrochloride (L700462) | 142373-60-2 | Tirofibanhydrochloride (also known as L700462 or MK383) is a novel non-peptide antagonist of glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) that is used as an antiplatelet drug. |
|
V2796 | Tirofiban hydrochloride hydrate (MK-383) | 150915-40-5 | Tirofiban (also known as L700462 or MK383) is a novel non-peptide antagonist of glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) that is used as an antiplatelet drug. |
|
V3020 | TR-14035 | 232271-19-1 | TR-14035 is a novel, dual antagonist of alpha4beta7 integrin with IC50 of 7 nM and alpha4beta1 integrin with IC50 of 87 nM. |
|
V35141 | Veltuzumab (IMMU-106; hA20) | 728917-18-8 | Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody (mAb). |
|
V81743 | VnP-16 | VnP-16 activates FAK by directly interacting with β1 integrin, thereby accelerating osteoblast differentiation and activity, thereby promoting bone formation. | |
|
V75808 | Volociximab (M200; Eos 200-4) | 558480-40-3 | Volociximab (M200) is a human/mouse chimeric IgG4 monoclonal antibody (mAb) IIA1 targeting integrin α5β1 (EC50=0.2 nM). |
|
V35113 | XVA143 | 264275-77-6 | XVA143 is an α/β-like isomeric antagonist that can inhibit LFA-1-dependent robust adhesion while enhancing shear flow and rolling adhesion. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
